Factors affecting adherence in patients with schizophrenia
DOI:
https://doi.org/10.18203/2349-3933.ijam20151483Keywords:
Adherence, Medication side-effects, SchizophreniaAbstract
Background: Nonadherence with medication regimens is among the most common causes of psychotic relapse and the need for rehospitalisation. This study was designed to look into the factors affecting attitude towards medication adherence in Schizophrenia and its relationship with severity of illness, side effects of medication.
Methods: Adult males and females in the age range of 18-55 years fulfilling criteria for schizophrenia according to ICD – 10, DCR, and reporting at outpatient department were taken up for this study. Severity of illness was assessed by Brief Psychiatric Rating Scale (BPRS), Side effects to medication were assessed by Udvalg for Kliniske Undersogelser (UKU) side effect scale, and Adherence was assessed by Medication adherence rating scale (MARS).
Results: Adherence negatively correlated with severity of illness, and side effects in the form of increased sleep duration, asthenia, increased fatigability, lassitude and diminished sexual desire. Regression analysis with MARS as dependent variable showed side effects of medication in the form of increased sleep duration in followed by asthenia, lassitude, and increased fatigability to be predictors of poor adherence in the sample.
Conclusions: Poor adherence is associated with severity of schizophrenia, sedation and asthenia like side effects due to medication. Sedation and asthenia like side effects caused a decline in adherence.
Metrics
References
Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Related Outcome Measures. 2014;5:43–62.
Kane JM. Compliance issues in outpatient treatment. J Clin Psychopharmacol. 1985;5(Suppl 3):S22-7.
Ayuso-Gutierrez JL, del Rio Vega JM. Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res. 1997;28:199-206.
Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull. 1997;23:637-51.
Kohn R ,Saxena S, Levav I,Saraceno B .World Health Organisation:The treatment gap in mental health care. 2004,82(11):858-66. Accessed 12 October 2015.
Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull .1995;21:419–29.
Johnson DAW, Pasterski JM, Ludlow JM, Street K, Taylor RD. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr Scand. 1983;67:339–52.
Kissling W. Compliance, quality assurrance and standards for relapse prevention in schizophrenia. Acta Psychiatrica Scandinavica.1994;89(Suppl):16-24.
McNabb WL. Adherence in diabetes: Can we define it and can we measure it? Diabetes Care.1997;20, 215-8.
World Health Organization: Adherence to long-term therapies: Evidence for action. Geneva, Switzerland http://www.who.int/chp/knowledge/publications/adherence_introduction.pdf . Accessed on 25 October, 2015.
Overall JE, Gorham DP. The brief psychiatric Rating Scale (BPRS) recent development in ascertainment and scaling. Psychopharmacology Bulletin. 1988;24(1):97-117.
Lingjaerde O, Ahlofors UG, Bech P, Dencker SJ, Elgen K. The UKU Side Effect Rating Scale. A New Comprehensive Rating Scale for Psychotropic Drugs and a Cross-Sectional Study of Side Effects in Neuroleptic Treated Patients". Acta Psychiatr Scand Suppl. 1987;334:1-100.
Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new medication adherence rating scale (MARS) for the psychoses. Schizophrenia Research. 2000;42(8):241-7.
Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug. Psychol Med.1983;13(1):177-83.
Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Medical Care.1986:24(1): 67-74.
Blackwell B. Commentry –the drug defaulter. Clinical Pharmacology and Therapeutics.1972; 13:841-50.
Conelly CE, Devenport YB. Adherence to treatment in lithium carbonate clinic. Arch Gen Psychiatry. 1982;39:585-8.
Miner CR, Rosenthal RN, Hellerstein DJ, Muenz LR. Prediction of compliance with outpatient referral in patients with schizophrenia and psychoactive substance use disorders. Arch Gen Psychiatry. 1997;54:706-12.
Robinson DG, Woerner MG, Alvir JM, Bilder RM, Hinrichsen GA, Lieberma JA. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophrenia Research. 2002;57:209–19.
Babiker IE. Noncompliance in schizophrenia. Psychiatric Developments. 1986;186:329–37.
Bebbington PE. The content and context of compliance. International Clinical Psychopharmacology. 1995;9(suppl 5):41–50.
Corriss DJ, Smith TE, Hull JW, Lim RW, Pratt SI, Romanelli S. Interactive risk factors for treatment adherence in a chronic psychotic disorders population. Psychiatry Res. 1999:89:269–74.
Marder SR, Mebane A, Chien CP, Winslade WJ, Swann E, Van Putten TA. Comparison of patients who refuse and consent to neuroleptic treatment. American Journal of Psychiatry. 1983;140:470–2.
Shepherd J. Tomorrow’s world: atherosclerosis in the year 2000. Neth J Med. 1997;50:221–7.
Olfson M, Mechanic D, Hansell S, Boyer CA, Walkup J, Weiden PJ. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv. 2000; 51:216–22.
Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents? American Journal of Psychiatry. 2002;159:103–8.
Allison DH, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry .2001;62(Suppl 7):22-31.
Chakos M, Lieberman L, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry. 2001;158:518-26.
Young JL, Zonana HV, Shepler L. Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law. 1986;14:105–22.
Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side¬effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res. 1999;35:51-68.
Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br Med J. 2000;321:1371-6.
Meyer PS, Bond GR, Tunis SL, McCoy ML. Comparison between the effects of atypical and traditional antipsychotics on work status for clients in a psychiatric rehabilitation program. J Clin Psychiatry. 2002;63:108-16.
Van-Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry.1974;31:67–72.
Van-Putten T, May PRA, Marder SR. Response to antipsychotic medication: The doctors and the con¬sumer's view. American Journal of Psychiatry. 1984;141:16-9.
Marder SR, May PRA. The benefits and limita¬tions of neuroleptics and other forms of treatment in schizophrenia. American Journal of Psychotherapy. 1986;40:357-69.
DelCampo EJ, Carr CF,Correa E. Rehospitalized schizophrenics: What they report about illness, treatment and compliance. Journal of Psychosocial Nursing and Mental Health Services.1983;21(6):29-33.
Falloon LR. Developing and maintaining adherence to long-term drug-taking regimens. Schizophr Bull. 1984;10:412-7.
Ludwig W, Huber D, Schmidt S, Bender W, Greil W. Assessment of compliance related attitudes in psychiatry. A comparison of two questionnaires based on the Health Belief Model. Soc Psychiatry Psychiatr Epidemiol. 1990; 25:298-303.
Downloads
Published
How to Cite
Issue
Section
